SAGE Therapeutics Inc SAGE Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Aug 22, 2018 (filed on Aug 23, 2018)

Insider Name:

Frates James M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-65

Price:

--
Aug 22, 2018 (filed on Aug 23, 2018)

Insider Name:

Frates James M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-700

Price:

--
Jun 19, 2018 (filed on Jun 20, 2018)

Insider Name:

Iguchi Kimi

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-800

Price:

--
Jun 19, 2018 (filed on Jun 20, 2018)

Insider Name:

Iguchi Kimi

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

800

Price:

$0.45
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Starr Kevin P

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Nayak Asha

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Paul Steven M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Germano Geno J

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Frates James M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Cola Michael F

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--

Filings by filing date

Aug 22, 2018 (filed on Aug 23, 2018)

Insider Name:

Frates James M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-65

Price:

--
Aug 22, 2018 (filed on Aug 23, 2018)

Insider Name:

Frates James M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-700

Price:

--
Jun 19, 2018 (filed on Jun 20, 2018)

Insider Name:

Iguchi Kimi

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-800

Price:

--
Jun 19, 2018 (filed on Jun 20, 2018)

Insider Name:

Iguchi Kimi

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

800

Price:

$0.45
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Starr Kevin P

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Nayak Asha

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Paul Steven M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Germano Geno J

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Frates James M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Jun 06, 2018 (filed on Jun 08, 2018)

Insider Name:

Cola Michael F

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	215 1st St CAMBRIDGE MA 02142-1213
Tel:	N/A
Website:	https://www.sagerx.com
IR:	See website

Key People

Kevin P. Starr Independent Chairman of the Board	Jeffrey M. Jonas President, Chief Executive Officer, Director	Kimi E. Iguchi Chief Financial Officer, Treasurer
Anne Marie Cook Senior Vice President, General Counsel, Secretary	Albert J. Robichaud Chief Scientific Officer	Michael Cloonan Chief Business Officer
Stephen J. Kanes Chief Medical Officer

Business Overview

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Financial Overview

For the six months ended 30 June 2018, SAGE Therapeutics Inc revenues increased from $0K to $90M. Net loss decreased 28% to $91.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income (expense), net increase from $1.4M to $8.7M (income), Other income (expense), net increase from $25K (expense) to $24K (income).

Employees:	257 as of Dec 31, 2017

Reporting Currency:	U.S. Dollars
Enterprise value:	$4,408M as of Jun 30, 2018
Annual revenue (TTM):	$90.00M as of Jun 30, 2018
EBITDA (TTM):	-$244.32M as of Jun 30, 2018
Net annual income (TTM):	-$234.72M as of Jun 30, 2018
Free cash flow (TTM):	-$185.79M as of Jun 30, 2018
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	46,664,296 as of Aug 1, 2018
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization